Shiloh
Editor, Senior Moderator
Source: https://jamanetwork.com/journals/jamaoncology/fullarticle/2782036
Research Letter
July 22, 2021
Incidence of Axillary Adenopathy in Breast Imaging After COVID-19 Vaccination
Kristin A. Robinson, MD1; Santo Maimone, MD1; Denise A. Gococo-Benore, MD2; et al Zhuo Li, MS3; Pooja P. Advani, MD4; Saranya Chumsri, MD4
JAMA Oncol. Published online July 22, 2021. doi:10.1001/jamaoncol.2021.3127
Vaccine-induced adenopathy after COVID-19 vaccination in breast imaging has received significant media attention, with evolving literary correspondence on management. Patients’ self-report of axillary swelling following COVID-19 vaccination was reported as high as 16%.1 The National Comprehensive Cancer Network and Society of Breast Imaging recommended to consider scheduling screening breast imaging 4 to 6 weeks after the second COVID-19 vaccination dose when possible.2 However, the actual incidence, timing, and characteristics of mammographic axillary adenopathy following COVID-19 vaccination remain uncertain...
Research Letter
July 22, 2021
Incidence of Axillary Adenopathy in Breast Imaging After COVID-19 Vaccination
Kristin A. Robinson, MD1; Santo Maimone, MD1; Denise A. Gococo-Benore, MD2; et al Zhuo Li, MS3; Pooja P. Advani, MD4; Saranya Chumsri, MD4
JAMA Oncol. Published online July 22, 2021. doi:10.1001/jamaoncol.2021.3127
Vaccine-induced adenopathy after COVID-19 vaccination in breast imaging has received significant media attention, with evolving literary correspondence on management. Patients’ self-report of axillary swelling following COVID-19 vaccination was reported as high as 16%.1 The National Comprehensive Cancer Network and Society of Breast Imaging recommended to consider scheduling screening breast imaging 4 to 6 weeks after the second COVID-19 vaccination dose when possible.2 However, the actual incidence, timing, and characteristics of mammographic axillary adenopathy following COVID-19 vaccination remain uncertain...